STOCK TITAN

GSK transfers 22M treasury shares for stock awards

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

On November 20, 2026, GSK plc transferred 22,000,000 treasury ordinary shares to JPMorgan Chase Bank, N.A., the depositary for its ADR programme, to procure the issuance and transfer of 11,000,000 ADRs to the GlaxoSmithKline (US) Trust for awards under three company plans. The consideration received from the Trust’s trustee was $47.82 per ADR, representing $23.91 per ordinary share, funded by a contribution to the Trust from GlaxoSmithKline LLC.

Following the transfer, GSK will hold 248,881,064 ordinary shares in treasury and have 4,067,451,066 ordinary shares in issue, excluding treasury shares. Treasury shares represent 6.12% of voting rights; the total number of voting rights is 4,067,451,066.

Treasury ordinary shares transferred 22,000,000 shares Transferred to the ADR depositary on November 20, 2026
ADRs to be issued and transferred 11,000,000 ADRs For the GlaxoSmithKline (US) Trust to use for awards
Consideration per ADR $47.82 per ADR Received from the Trust’s trustee
Consideration per ordinary share $23.91 per ordinary share Represented by the consideration per ADR
Ordinary shares held in treasury 248,881,064 shares Following the transfer
Ordinary shares in issue excluding treasury shares 4,067,451,066 shares Following the transfer
Voting rights attributable to treasury shares 6.12% Following the transfer
American depositary receipts financial
"American depositary receipts (“ADR”) programme"
A certificate traded on U.S. markets that represents ownership of shares in a foreign company, letting U.S. investors buy and sell that company as if it were listed domestically. Think of it as a local voucher for a foreign product: it makes price quotes in dollars, trades on familiar exchanges, and brings differences in liquidity, fees and legal protections that can affect returns and risk compared with buying the underlying foreign shares directly.
Treasury Shares technical
"shares ... held by the Company in treasury (“Treasury Shares”)"
Treasury shares are a company’s own stock that it has repurchased and keeps on its books instead of canceling or leaving in the hands of outside investors. Think of them like coupons a business puts back in a drawer: they don’t vote or receive dividends while held, but they can be reissued later for employee pay or fundraising. For investors this matters because buybacks change the number of shares that count toward earnings and ownership, can boost per‑share metrics, and use corporate cash that might otherwise go to growth or dividends.
Deferred Annual Bonus Plan technical
"awards granted under the Company’s Deferred Annual Bonus Plan"
Performance Share Plan technical
"awards granted under the Company’s ... Performance Share Plan"
A performance share plan grants company shares to employees or executives only if the business meets specific targets over a set period, so the reward depends on results rather than being automatic. For investors it matters because it aligns managers’ pay with company performance—like promising a team stock instead of cash if they hit goals—which can influence future share count, shareholder value, and how confidently management pursues growth.
Share Value Plan technical
"awards granted under the Company’s ... Share Value Plan"
Disclosure Guidance and Transparency Rules regulatory
"Financial Conduct Authority's Disclosure Guidance and Transparency Rules"
Disclosure guidance and transparency rules are the standards and regulations that require companies to share clear, timely information about their finances, risks, operations and material events. They matter to investors because consistent, honest reporting is like a car’s dashboard — it reveals the data you need to judge safety and performance and make informed buying or selling decisions. Strong disclosure reduces surprises and helps keep markets fair and efficient.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many GSK shares were transferred for awards?

GSK transferred 22,000,000 treasury ordinary shares to its ADR depositary to procure 11,000,000 ADRs for the Trust, for use in satisfying awards under the company’s Deferred Annual Bonus Plan, Performance Share Plan and Share Value Plan.

What consideration was received for the GSK share transfer?

The consideration received from the Trust’s trustee was $47.82 per ADR, representing $23.91 per ordinary share. GlaxoSmithKline LLC funded the consideration through a contribution to the Trust.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of November 2026
 
Commission File Number 001-15170
 
 
GSK plc
(Translation of registrant's name into English)
 
 
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
 
Issued: 20 November 2026, London UK
 
Transfer of Treasury Shares


 
On 20 November 2026, GSK plc (the “Company”) transferred 22,000,000 ordinary shares of 31¼ pence each (“Ordinary Shares”) that were held by the Company in treasury (“Treasury Shares”) to JPMorgan Chase Bank, N.A., the depositary of the Company’s American depositary receipts (“ADR”) programme, to procure the issuance and transfer of 11,000,000 ADRs of the Company to the GlaxoSmithKline (US) Trust (the “Trust”), to be used to satisfy awards granted under the Company’s Deferred Annual Bonus Plan, Performance Share Plan and Share Value Plan. The consideration received from the trustee of the Trust, of $47.82 per ADR, representing $23.91 per Ordinary Share, was funded by a contribution to the Trust from GlaxoSmithKline LLC.
 
Following the transfer, the Company will hold 248,881,064 Ordinary Shares in treasury and have 4,067,451,066 Ordinary Shares in issue (excluding Treasury Shares).
 
The total number of voting rights in the Company is 4,067,451,066. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
 
The Company confirms that, in accordance with DTR 5.5.1R, following the above transfer the percentage of voting rights attributable to the Treasury Shares is 6.12%.
 
This announcement is made in accordance with the requirements of UK Listing Rule 9.8.2.
 
Notifications may be sent to company.secretary@gsk.com.
 
 
V A Whyte
Company Secretary
 
20 November 2026
  
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
  
Registered in England & Wales:
No. 3888792

Registered Office:
79 New Oxford Street
London
WC1A 1DG
 

 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
GSK plc
 
(Registrant)
 
 
Date: November 20, 2026
 
 
 
 
By:/s/ VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GSK plc
 

Keep reading